Log in to search using one of your social media accounts:


Genelux begins dosing in Phase II ovarian cancer trial

US-based oncolytic immunotherapy developer Genelux has started dosing patients in a Phase II clinical trial (VIRO-15) of its clinical-stage candidate GL-ONC1 to treat recurrent ovarian cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusions: The ovary is a common site of metastases from GI, breast, liver, pancreas, kidney cancers, but very rarely from a primary lung (0.3-4%). Immunotherapy could be an useful therapeutic option for treatment expecially in young patients.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
Authors: Jazaeri AA PMID: 29200418 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne CDx™, the company’s comprehensive companion diagnostic test for solid tumors. FoundationOne CDx is intended for use by health care professionals to help inform cancer treatment management in accordance with professional guidelines for patients with solid tumors. The first and only FDA-approved test of its kind for all solid tumors, FoundationOne CDx is a diagnostic test that acts as: “Access to important genomic information is ...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news
The immunotherapy technology is being developed initially to treat ovarian cancer.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
A California biotechnology company has signed an agreement with Moffitt Cancer Center in Tampa to do the research and development work for a potential immunotherapy to treat ovarian cancer. ITUS Corp. (NASDAQ: ITUS), based in San Jose, California, will pay Moffitt about $1.2 million over two years, as part of a cooperative research and development agreement, Amit Kuman, president and CEO of ITUS, said in a conference call Tuesday. Leading the work will be Dr. Jose Conejo Garcia, a M offitt researcher…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Immunotherapies, particularly checkpoint inhibitors, have set off a revolution in cancer therapy by releasing the power of the immune system. However, only little is known about the antigens that are essentially presented on cancer cells, capable of exposing them to immune cells. Large-scale HLA ligandome analysis has enabled us to...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: PNAS Plus Source Type: research
ERRATUM. Oncol Res. 2017 Nov 02;25(9):1665 Authors: Zhang T, Ye L, He Q, Zhu J Abstract Ovarian cancer is highly malignant with a gradually increasing incidence and a high mortality rate. Immunosuppression is induced in ovarian cancer, although the mechanism detail is not clear. It has been indicated that HVEM (herpesvirus entry mediator) B- and T-lymphocyte attenuator (BTLA) negatively regulates the immune responses of T lymphocytes. Here, HVEM mRNA was found to be elevated in ovarian cancer tissue samples and primary ovarian cancer cells in comparison with benign tissue samples. We then knocked down ...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
We present the challenges and the opportunities of using immune checkpoint inhibitors against these endocrine malignancies, highlighting the breakthroughs and pitfalls that have recently emerged.
Source: Endocrine-Related Cancer - Category: Endocrinology Authors: Tags: Thematic Review Source Type: research
Identification of immune targets for cancer immunoprevention, or immunotherapy, has historically focused on tumor-associated (self) antigens or neoantigens expressed on malignant cells. For self-antigens, overcoming tolerance can be a difficult challenge. Neoantigens do not suffer from this limitation, but the lack of recurrent mutations yielding common neoantigens that can be exploited in vaccines is a problem for many tumor types. Targeting "retired antigens," a specialized type of self-antigen, may have considerable advantages. Antigens no longer expressed in mature or aged individuals should pose reduced risk...
Source: Cancer Prevention Research - Category: Cancer & Oncology Authors: Tags: Editorials Source Type: research
Condition:   Platinum Resistant Ovarian Cancer Interventions:   Procedure: Leukapheresis;   Drug: Utomilumab;   Drug: Cyclophosphamide;   Biological: T Cell Infusion;   Drug: Interleukin-2 Sponsors:   M.D. Anderson Cancer Center;   Immatics US, Inc.;   Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Ovarian Cancer | Ovaries | Pharmaceuticals